Johannes Jacob Pieter Kastelein, Chief Scientific Officer at NewAmsterdam Pharma Co N.V. (NAMS), sold 50,246 shares at $25.03 ($1.3M) on 2026-09-30, disclosed to the SEC on 2026-10-02.
Scheduled sale ($1.3M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NAMS | SELL | 2026-02-24 | $1.6M | — | Filing → |
| NAMS | SELL | 2026-01-07 | $200K | — | Filing → |
| NAMS | SELL | 2025-08-25 | $3.7M | — | Filing → |